Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66. doi: 10.1007/s00280-014-2590-x. Epub 2014 Sep 23.

PMID:
25245821
[PubMed - indexed for MEDLINE]
2.

ALK inhibitors and advanced non-small cell lung cancer (review).

Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C.

Int J Oncol. 2014 Aug;45(2):499-508. doi: 10.3892/ijo.2014.2475. Epub 2014 May 29. Review.

PMID:
24889366
[PubMed - indexed for MEDLINE]
4.

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M.

J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.

PMID:
24807156
[PubMed - indexed for MEDLINE]
5.

Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A.

J Thorac Oncol. 2014 May;9(5):692-701. doi: 10.1097/JTO.0000000000000127.

PMID:
24633407
[PubMed - indexed for MEDLINE]
6.

Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.

Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, Nagata K, Masago K, Kaji R, Fujita S, Tachikawa R, Otsuka K, Otsuka K, Tomii K.

Anticancer Res. 2014 Jan;34(1):275-81.

PMID:
24403474
[PubMed - indexed for MEDLINE]
7.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.

PMID:
24390424
[PubMed - indexed for MEDLINE]
8.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

PMID:
24356624
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR.

J Thorac Oncol. 2013 Dec;8(12):1519-28. doi: 10.1097/JTO.0000000000000009.

PMID:
24189513
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.

J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21.

PMID:
24145346
[PubMed - indexed for MEDLINE]
Free Article
11.

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R.

J Clin Pharmacol. 2014 Mar;54(3):253-7. doi: 10.1002/jcph.191. Epub 2013 Oct 22.

PMID:
24122760
[PubMed - indexed for MEDLINE]
12.

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study.

Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ.

Clin Transl Oncol. 2014 May;16(5):463-8. doi: 10.1007/s12094-013-1102-5. Epub 2013 Sep 4.

PMID:
24002945
[PubMed - indexed for MEDLINE]
13.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N.

Lung Cancer. 2013 Nov;82(2):276-81. doi: 10.1016/j.lungcan.2013.08.002. Epub 2013 Aug 13.

PMID:
23992877
[PubMed - indexed for MEDLINE]
Free Article
14.

Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR.

Lung Cancer. 2013 Oct;82(1):121-7. doi: 10.1016/j.lungcan.2013.07.021. Epub 2013 Aug 7.

PMID:
23973203
[PubMed - indexed for MEDLINE]
Free Article
15.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH.

Br J Cancer. 2013 Sep 17;109(6):1476-81. doi: 10.1038/bjc.2013.472. Epub 2013 Aug 13.

PMID:
23942074
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T.

Med Oncol. 2013;30(3):676. doi: 10.1007/s12032-013-0676-7. Epub 2013 Aug 8.

PMID:
23925664
[PubMed - indexed for MEDLINE]
18.

Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.

Socinski MA, Govindan R, Spigel D.

Clin Adv Hematol Oncol. 2012 Oct;10(10 Suppl 18):1-16.

PMID:
23187688
[PubMed - indexed for MEDLINE]
19.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V.

Invest New Drugs. 2014 Feb;32(1):123-34. doi: 10.1007/s10637-013-9958-3. Epub 2013 Apr 12.

PMID:
23579358
[PubMed - indexed for MEDLINE]
20.

[Analysis of drug therapy of lung cancer in Hungary].

Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Kovács G.

Magy Onkol. 2013 Mar;57(1):33-8. doi: MagyOnkol.2013.57.1.33. Epub 2012 Dec 20. Hungarian.

PMID:
23573520
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk